Equibles does not estimate personal net worth.
Get an email with a short summary when Pelthos Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get PTHS alertsScott Plesha is recorded as Board Member at Pelthos Therapeutics Inc. (PTHS) since January 1, 2025 and CEO at Pelthos Therapeutics Inc. (PTHS). The newest filing on record that lists Scott Plesha as CEO and Board Member at Pelthos Therapeutics Inc. (PTHS) is dated August 18, 2026. Pelthos Therapeutics Inc. reported in an 8-K filed October 1, 2026 that Scott Plesha was appointed director, effective September 29, 2026. Pelthos Therapeutics Inc. reported in an 8-K filed July 2, 2025 that Scott Plesha was appointed Chief Executive Officer, effective July 1, 2025. Pelthos Therapeutics Inc. reported in an 8-K filed July 2, 2025 that Scott Plesha was appointed President, effective July 1, 2025. Equibles holds 4 filed executive changes naming Scott Plesha; each is listed under recent activity with its source filing. The proxy statement of Pelthos Therapeutics Inc. reports total compensation of $4,153,168 for Scott Plesha in fiscal 2025, including a base salary of $219,802. Disclosed compensation is on record for 2 fiscal years. Scott Plesha has spoken on 3 earnings calls across 1 company, most recently for Pelthos Therapeutics Inc. on August 13, 2026. Pelthos Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Pelthos Therapeutics Inc. includes Christian Kopfli (CEO), Francis Knuettel II (CEO, CFO and Chief Accounting Officer), Frank Knuettel (CFO) and 7 others.
“The eight (8) nominees named in the Proxy Statement were elected to serve as the Company’s directors until the Company’s 2027 Annual Meeting of Stockholders, or until each of their respective successors are elected and qualified or until their earlier resignation or removal.”
“In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers of the Company: | **Name of Executive Officer** | **Age** | **Position** | | --- | --- | --- | | Scott Plesha | 61 | Chief Executive Officer, President and Director | | Francis Knuettel II | 59 | Chief Financial Officer (principal financial officer and principal accounting officer) | | Sai Rangarao | 41 | Chief Commercial Officer |”
“We're delighted to be with you today and share with you our second quarter 2026 operating results and highlights. Joining me today are John Gay, our Chief Financial Officer, and Cy Rangaro, our Chief Commercial Officer.”
“We're delighted to be with you today to share with you our first quarter 2026 operating results and highlights. Joining me today are John Gay, our Chief Financial Officer, and Cy Rangaro, our Chief Commercial Officer.”
“We're delighted to be with you today and share with you our third quarter operating results and highlights. Joining me today are Frank Knuettel, our Chief Financial Officer; and Sai Rangarao, Pelthos Therapeutics Chief Commercial Officer.”
SEC 8-K
2025-07-01–present
2025-01-01–present
Last confirmed August 18, 2026
Start not stated–present
Last confirmed August 18, 2026
Biotechnology · Healthcare
CEO, Board Member
2025-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pelthos Therapeutics Inc. (PTHS) | Chief Executive Officer | $219,802 | $4,153,168 |
| 2024 | Pelthos Therapeutics Inc. (PTHS) | Chief Executive Officer | — | — |
